Gastric Adenocarcinoma

  • Gareth Eeson
  • Savtaj S. Brar
  • Natalie G. Coburn
Chapter
First Online:

Abstract

Gastric cancer remains a leading cause of cancer mortality worldwide, but demonstrates wide geographic variation in its incidence. Highest incidences are observed in East Asian countries, where rates of gastric cancer are five- to tenfold the rates observed in Canada. In North America, the majority of patients diagnosed with gastric cancer have advanced disease at presentation. Surgical resection with appropriate lymphadenectomy remains the mainstay of treatment for patients presenting with locoregional disease. Endoscopic resection can be considered in highly selected patients presenting with early cancers. Advances in systemic therapy for gastric adenocarcinoma have led to improved survival in both the adjuvant and metastatic setting. Radiotherapy plays an important role in both the adjuvant and palliative setting. The complex multidisciplinary management of gastric cancer remains in evolution as we strive to further improve outcomes in this patient population.

Keywords

Gastric cancer Gastric adenocarcinoma Lymphadenectomy Endoscopic ultrasound Diagnostic laparoscopy 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Canadian Cancer Society. Canadian Cancer Society’s Steering Committee: Canadian Cancer Statistics 2014. Toronto: Canadian Cancer Society; 2014.Google Scholar
  2. 2.
    Kim JP. Surgical results in gastric cancer. Semin Surg Oncol. 1999;17(2):132–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Kim JP, Hur YS, Yang HK. Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol. 1995;2(4):308–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Survival rates for stomach cancer, by stage. [cited 2014 November 1]; Available from: http://cancer.org/Cancer/StomachCancer/DetailedGuide/stomach-cancer-survival-rates.
  5. 5.
    Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  6. 6.
    Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. American Joint Committee on cancer staging manual. New York: Springer; 2009.Google Scholar
  7. 7.
    Gouzi JL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg. 1989;209(2):162–6.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mahar AL, et al. A systematic review of surgery for non-curative gastric cancer. Gastric Cancer. 2012;15 Suppl 1:S125–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Bonenkamp JJ, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.CrossRefPubMedGoogle Scholar
  10. 10.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRefGoogle Scholar
  11. 11.
    Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol. 2006;22(5):561–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2009;4:CD004276.PubMedGoogle Scholar
  13. 13.
    Degiuli M, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim SH, et al. Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg. 1999;3(1):24–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Gastric Cancer, in NCCN Clinical Practice Guidelines in Oncology 2015. National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology Gastric Cancer v3.2015. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
  16. 16.
    Brar S, et al. Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013;217(2):347–57. e1.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim W, et al. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2015;263(1):28–35.Google Scholar
  18. 18.
    Cunningham D, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Macdonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Knight G, Earle CC, Cosby R, Coburn N, Youssef Y, Spithoff K, Malthaner R, Wong RKS, The Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for resectable gastric cancer, Evidence-based series 2-14 version 3.2011. Toronto: Cancer Care Ontario; 2011.Google Scholar
  21. 21.
    Lowy AM, et al. Laparoscopic staging for gastric cancer. Surgery. 1996;119(6):611–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Oh CA, et al. Long-term results and prognostic factors of gastric cancer patients with only positive peritoneal lavage cytology. J Surg Oncol. 2012;105(4):393–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Songun I, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.CrossRefPubMedGoogle Scholar
  24. 24.
    Sasako M, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Hirao M, et al. Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial. Surgery. 2015;157(6):1099–105.CrossRefPubMedGoogle Scholar
  26. 26.
    Fujita J, et al. Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. Gastric Cancer. 2012;15(1):42–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Kim HI, et al. Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893]. BMC Cancer. 2014;14:209.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fujitani K, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318.Google Scholar
  29. 29.
    Bonenkamp JJ, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Cuschieri A, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Cuschieri A, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9-10):1522–30.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Degiuli M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol. 2004;30(3):303–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Paoletti X, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37.CrossRefPubMedGoogle Scholar
  34. 34.
    Noh SH, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.CrossRefPubMedGoogle Scholar
  35. 35.
    Lee J, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.CrossRefPubMedGoogle Scholar
  36. 36.
    Park SH et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.Google Scholar
  37. 37.
    Glimelius B, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMedGoogle Scholar

Copyright information

© University of Toronto General Surgery Oncology Program 2016

Authors and Affiliations

  • Gareth Eeson
    • 1
  • Savtaj S. Brar
    • 2
  • Natalie G. Coburn
    • 3
  1. 1.General Surgical OncologyUniversity of TorontoTorontoCanada
  2. 2.Department of SurgeryUniversity of TorontoTorontoCanada
  3. 3.Department of SurgerySunnybrook Health Sciences Centre, University of TorontoTorontoCanada

Personalised recommendations